1
|
Abbott S, Ibarcena D, Gwinn T, Struzik A, Halaki M, Kaloti G, Salter J, Cobley S. Longitudinal changing relationships between growth tempo and vertical stiffness in movement across maturation. Hum Mov Sci 2023; 87:103039. [PMID: 36446274 DOI: 10.1016/j.humov.2022.103039] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2022] [Revised: 11/11/2022] [Accepted: 11/14/2022] [Indexed: 11/27/2022]
Abstract
PURPOSE To determine whether average growth tempo influenced longitudinal relationships between maturity status and coordination capability using a 15-s hopping task (Aim 1). To investigate how differences in absolute growth tempo were associated with change in coordination capability within and across peak growth (Aim 2). METHODS Participants were N1 = 110 (Aim 1) and N2 = 71 (Aim 2) Australian male competitive swimmers, aged 10-15 years, exposed to repeated-measures tracking (2-years, and 12-months respectively) of maturity status, growth tempo and movement coordination capability. Coordination capability was estimated via vertical stiffness (KV) in a hopping task, reflected by participant mean KV and between-jump coefficient of variation (CV). RESULTS For Aim 1, log-linear mixed model trends identified maturity status and growth tempo were significantly associated with KV mean and KV CV. For a given maturity status, mean KV was 9% lower in the 'High' average growth tempo group than the 'Low' average tempo group. For Aim 2, mixed repeated-measures analyses of variance identified how time points of increased growth tempo were significantly associated with 7-11% reductions in mean KV, with similar mean KV decrements irrespective of growth tempo group. Meanwhile, KVCV only illustrated progressive longitudinal reductions. CONCLUSIONS Within maturational progression, short-term accelerations in growth tempo corresponded with short-term decreases in KV mean, suggesting temporary disruptions to movement coordination capability. Measuring growth tempo and applying hopping tasks in specific movement contexts could help consistently identify disturbances in motor coordination.
Collapse
Affiliation(s)
- Shaun Abbott
- Sydney School of Health Sciences, Faculty of Medicine & Health, The University of Sydney, New South Wales 2141, Australia
| | - Daniel Ibarcena
- Sydney School of Health Sciences, Faculty of Medicine & Health, The University of Sydney, New South Wales 2141, Australia
| | - Tom Gwinn
- Sydney School of Health Sciences, Faculty of Medicine & Health, The University of Sydney, New South Wales 2141, Australia
| | - Artur Struzik
- Department of Biomechanics, Wroclaw University of Health and Sport Sciences, Wroclaw, Poland
| | - Mark Halaki
- Sydney School of Health Sciences, Faculty of Medicine & Health, The University of Sydney, New South Wales 2141, Australia
| | - Gurleen Kaloti
- Sydney School of Health Sciences, Faculty of Medicine & Health, The University of Sydney, New South Wales 2141, Australia
| | - James Salter
- Swimming Australia Ltd, Sunnybank, Queensland, Australia
| | - Stephen Cobley
- Sydney School of Health Sciences, Faculty of Medicine & Health, The University of Sydney, New South Wales 2141, Australia.
| |
Collapse
|
2
|
Hogan C, Abbott S, Halaki M, Torres Castiglioni M, Yamauchi G, Mitchell L, Salter J, Romann M, Cobley S. Maturation-based Corrective Adjustment Procedures (Mat-CAPs) in youth swimming: Evidence for restricted age-group application in females. PLoS One 2022; 17:e0275797. [PMID: 36206228 PMCID: PMC9543692 DOI: 10.1371/journal.pone.0275797] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2021] [Accepted: 09/23/2022] [Indexed: 11/05/2022] Open
Abstract
Inter-individual differences in maturation-associated development can lead to variations in physical performance, resulting in performance (dis)advantages and maturation selection bias within youth sport systems. To address such bias and account for maturational differences, Maturation-based Corrective Adjustment Procedures (Mat-CAPs) could be beneficial. The present study aimed to: (1) determine maturity timing distributions in youth female swimming; (2) quantify the relationship between maturation status and 100-m front-crawl (FC) performance; (3) implement Mat-CAPs to remove maturational influences upon swimming performance. For Aim 1 and 2, participants were 663 female (10–15 years) swimmers who participated in 100-m FC events at Australian regional, state, and national-level competitions between 2016–2020 and underwent anthropometric assessment (mass, height and sitting height) to estimate maturity timing and offset. For Aim 3, participants aged 10–13 years were categorised into maturity timing categories. Maturity timing distributions for Raw (‘All’, ‘Top 50%’ and ‘Top 25%’) and Correctively Adjusted swim times were examined. Chi-square, Cramer’s V and Odds Ratios determined the presence of maturation biases, while Mat-CAPs identified whether such biases were removed in targeted age and selection-groups. Results identified that between 10–13 years, a significantly higher frequency of ‘early’ maturers was apparent, although tapered toward higher frequencies of ‘Late-normative’ maturers by 14–15 years. A curvilinear relationship between maturity-offset and swim performance was identified (R2= 0.51, p<0.001) and utilised for Mat-CAPs. Following Mat-CAPs application, maturity timing biases evident in affected age-groups (10–13 years), and which were magnified at higher selection levels (‘Top 50%’ & ‘25%’ of swim performances) were predominantly removed. Findings highlight how maturation advantages in females occurred until approximately 13 years old, warranting restricted Mat-CAPs application. Mat-CAPS has the potential to improve female swimmer participation experiences and evaluation.
Collapse
Affiliation(s)
- Clorinda Hogan
- Sydney School of Health Sciences, Faculty of Medicine & Health, The University of Sydney, Camperdown, New South Wales, Australia
| | - Shaun Abbott
- Sydney School of Health Sciences, Faculty of Medicine & Health, The University of Sydney, Camperdown, New South Wales, Australia
| | - Mark Halaki
- Sydney School of Health Sciences, Faculty of Medicine & Health, The University of Sydney, Camperdown, New South Wales, Australia
| | - Marcela Torres Castiglioni
- Sydney School of Health Sciences, Faculty of Medicine & Health, The University of Sydney, Camperdown, New South Wales, Australia
| | - Goshi Yamauchi
- Sydney School of Health Sciences, Faculty of Medicine & Health, The University of Sydney, Camperdown, New South Wales, Australia
| | | | - James Salter
- Swimming Australia Limited, Sunnybank, Queensland, Australia
| | - Michael Romann
- Swiss Federal Institute of Sport Magglingen, Magglingen, Switzerland
| | - Stephen Cobley
- Sydney School of Health Sciences, Faculty of Medicine & Health, The University of Sydney, Camperdown, New South Wales, Australia
- * E-mail:
| |
Collapse
|
3
|
Abbott S, Castiglioni M, Cobley S, Halaki M, Hogan C, Mitchell L, Romann M, Salter J, Yamauchi G. Removing maturational influences from female youth swimming: the application of corrective adjustment procedures. J Sci Med Sport 2021. [DOI: 10.1016/j.jsams.2021.09.098] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
4
|
Morrissey K, Spooner F, Salter J, Shaddick G. Area level deprivation and monthly COVID-19 cases: The impact of government policy in England. Soc Sci Med 2021; 289:114413. [PMID: 34563867 PMCID: PMC8459718 DOI: 10.1016/j.socscimed.2021.114413] [Citation(s) in RCA: 20] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2021] [Revised: 08/25/2021] [Accepted: 09/17/2021] [Indexed: 01/08/2023]
Abstract
This paper aims to understand the relationship between area level deprivation and monthly COVID-19 cases in England in response to government policy throughout 2020. The response variable is monthly reported COVID-19 cases at the Middle Super Output Area (MSOA) level by Public Health England, with Index of Multiple Deprivation (IMD), ethnicity (percentage of the population across 5 ethnicity categories) and the percentage of the population older than 70 years old and time as predictors. A GEE population-averaged panel-data model was employed to model trends in monthly COVID-19 cases with the population of each MSOA included as the exposure variable. Area level deprivation is significantly associated with COVID-19 cases from March 2020; however, this relationship is reversed in December 2020. Follow up analysis found that this reversal was maintained when controlling for the novel COVID-19 variant outbreak in the South East of England. This analysis indicates that changes in the role of deprivation and monthly reported COVID-19 over time cases may be linked to two government policies: (1) the premature easing of national restrictions in July 2020 when cases were still high in the most deprived areas in England and (2) the introduction of a regional tiered system in October predominantly in the North of England. The analysis adds to the evidence showing that deprivation is a key driver of COVID-19 outcomes and highlights the unintended negative impact of government policy.
Collapse
Affiliation(s)
- Karyn Morrissey
- DTU Management, Department of Technology, Management and Economics, Technical University of Denmark, Demark; European Centre for Environment and Human Health, University of Exeter, UK; Alan Turing Institute, London, UK.
| | - Fiona Spooner
- European Centre for Environment and Human Health, University of Exeter, UK.
| | - James Salter
- Mathematics, School of Engineering, Mathematics and Physical Sciences, University of Exeter, UK; Joint Centre for Excellence in Environmental Intelligence, Exeter, UK.
| | - Gavin Shaddick
- Mathematics, School of Engineering, Mathematics and Physical Sciences, University of Exeter, UK; Joint Centre for Excellence in Environmental Intelligence, Exeter, UK; Alan Turing Institute, London, UK.
| |
Collapse
|
5
|
Abbott S, Hogan C, Castiglioni MT, Yamauchi G, Mitchell LJG, Salter J, Romann M, Cobley S. Maturity-related developmental inequalities in age-group swimming: The testing of 'Mat-CAPs' for their removal. J Sci Med Sport 2020; 24:397-404. [PMID: 33172611 DOI: 10.1016/j.jsams.2020.10.003] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2020] [Revised: 10/03/2020] [Accepted: 10/06/2020] [Indexed: 10/23/2022]
Abstract
OBJECTIVES To (1) examine the association between maturity timing and performance-based selection levels in (N=708) Australian male 100-m Freestyle swimmers (12-17 years); (2) identify the relationship between maturation status and 100-m Freestyle performance; and (3) determine whether Maturation-based Corrective Adjustment Procedures (Mat-CAPs) could remove maturation-related differences in swimming performance. METHODS In Part 1, maturity timing category distributions ('Early', 'Early Normative', 'Late Normative' and 'Late') for 'All', 'Top 50%' and '25%' of raw swimming times were examined within and across age-groups. In Part 2, multiple regression analyses quantified the relationship between maturity offset (YPHV) and swimming performance. In Part 3, sample-based maturity timing category distributions were examined based on raw and correctively adjusted swim times for 12-17 year old age-groups. RESULTS Based on raw swim times, a high prevalence of 'Early-maturing' swimmers, with large effect sizes was identified (e.g., 14 years 'All' - χ2 (3, 151=111.98, p<0.001; 'Early' v 'Late' OR=82.0 95%CI=4.77, 1409.9); while a complete absence of 'Late-maturers' was apparent in the sample (N=708). When maturity categories were re-defined based on sample mean±standard deviation, and when using the expected curvilinear trendline identified in Part 2, Mat-CAPs mitigated maturity timing biases across all age-groups and selection levels, and removed the Freestyle performance advantage afforded by advanced maturity timing and status. CONCLUSIONS Removing the influence of maturation-related developmental differences could help improve youth swimmer participation experiences and improve the accuracy of identifying genuinely skilled age-group swimmers.
Collapse
Affiliation(s)
- Shaun Abbott
- Sydney School of Health Sciences, Faculty of Medicine & Health, The University of Sydney, Australia
| | - Clorinda Hogan
- Sydney School of Health Sciences, Faculty of Medicine & Health, The University of Sydney, Australia
| | | | - Goshi Yamauchi
- Sydney School of Health Sciences, Faculty of Medicine & Health, The University of Sydney, Australia
| | | | | | - Michael Romann
- Swiss Federal Institute of Sport Magglingen, Switzerland
| | - Stephen Cobley
- Sydney School of Health Sciences, Faculty of Medicine & Health, The University of Sydney, Australia.
| |
Collapse
|
6
|
Abbott S, Moulds K, Salter J, Romann M, Edwards L, Cobley S. Testing the application of corrective adjustment procedures for removal of relative age effects in female youth swimming. J Sports Sci 2020; 38:1077-1084. [PMID: 32202222 DOI: 10.1080/02640414.2020.1741956] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Abstract
The purpose of this study was (1) accurately estimate longitudinal relationships between decimal age (i.e., chronological and relative) and performance in Australian female 100 m (N = 765) and 200 m (N = 428) Breaststroke swimmers (10-18 years); and (2) determine whether corrective adjustment procedures could remove Relative Age Effects (RAEs) in an independent sample of age-matched 100 m (N = 2,491) and 200 m (N = 1,698) state/national level Breaststroke swimmers. In Part 1, growth curve modelling quantified longitudinal relationships between decimal age and swimming performance. In Part 2, relative age distributions (Quartile 1-4) for "All", "Top 25%" and "10%" of swimming times were examined based on raw and correctively adjusted swim times for age-groups. Based on raw swim times, finding identified RAE effect sizes increased in magnitude (small-medium) with selection level ("All"-"Top 25%") in 12-14 years age-groups for both events. However, when correctively adjusted swim performances were examined, RAEs were primarily absent across all age-groups and selection levels. Using longitudinal reference data, corrective adjustment procedures removed relative age advantages in female youth Breaststroke performance. Removing the influence of relative age-related differences is predicted to improve the accuracy of identifying genuinely skilled youth swimmers.
Collapse
Affiliation(s)
- Shaun Abbott
- Discipline of Exercise & Sport Science, Faculty of Health Sciences, The University of Sydney , Sydney, Australia
| | - Kylie Moulds
- Discipline of Exercise & Sport Science, Faculty of Health Sciences, The University of Sydney , Sydney, Australia
| | | | - Michael Romann
- Swiss Federal Institute of Sport , Magglingen, Switzerland
| | - Lucy Edwards
- Discipline of Exercise & Sport Science, Faculty of Health Sciences, The University of Sydney , Sydney, Australia
| | - Stephen Cobley
- Discipline of Exercise & Sport Science, Faculty of Health Sciences, The University of Sydney , Sydney, Australia
| |
Collapse
|
7
|
Cobley S, Abbott S, Dogramaci S, Kable A, Salter J, Hintermann M, Romann M. Transient Relative Age Effects across annual age groups in National level Australian Swimming. J Sci Med Sport 2018; 21:839-845. [DOI: 10.1016/j.jsams.2017.12.008] [Citation(s) in RCA: 27] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2017] [Revised: 11/23/2017] [Accepted: 12/21/2017] [Indexed: 12/12/2022]
|
8
|
Arnedos M, Drury S, Afentakis M, A'Hern R, Hills M, Salter J, Smith IE, Reis-Filho JS, Dowsett M. Biomarker changes associated with the development of resistance to aromatase inhibitors (AIs) in estrogen receptor-positive breast cancer. Ann Oncol 2014; 25:605-610. [PMID: 24525703 PMCID: PMC3933249 DOI: 10.1093/annonc/mdt575] [Citation(s) in RCA: 37] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2013] [Revised: 11/08/2013] [Accepted: 11/18/2013] [Indexed: 12/28/2022] Open
Abstract
BACKGROUND The purpose of this study was to identify any differences in key biomarkers associated with estrogen action between biopsies taken at diagnosis and at recurrence or progression during treatment with an aromatase inhibitor (AI). PATIENTS AND METHODS Patients were retrospectively identified from a clinical database as having relapsed or progressed during AI treatment. Immunohistochemistry was carried out against estrogen receptor (ER), progesterone receptor (PgR), human epidermal growth factor receptor 2 (HER2), insulin-like growth factor type-1 receptor (IGF1R), insulin receptor substrate-1 (IRS-1), stathmin, phosphatase and tensin homolog and Ki67. RESULTS Fifty-five pairs of samples were identified with ER- and/or PgR-positive diseases. Four (7%) patients were ER-negative at progression. Overall, PgR levels were lower in the recurrence sample, but 35% of cases remained positive. IGF1R levels decreased significantly. There were no substantial changes in HER2, IRS-1 or stathmin levels to indicate a role in resistance. Higher Ki67 levels at resistance indicate more proliferative disease. CONCLUSIONS The phenotype of AI-recurrent lesions shows high between-tumour heterogeneity. There is evidence of an increase in Ki67, a reduction in IGF1R and a loss of ER expression in some individuals and some activation of growth factor signalling pathways that may explain resistance in individuals and merit treatment targeted to those pathways. Biopsy at recurrence will be necessary to identify the relevant target for individuals.
Collapse
Affiliation(s)
- M Arnedos
- Breast Cancer Unit, Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France
| | - S Drury
- NE Thames Regional Genetics Laboratory, Great Ormond Street Hospital, London
| | - M Afentakis
- Academic Department of Biochemistry, Royal Marsden Hospital, London
| | - R A'Hern
- Clinical Trials and Statistics Unit, The Institute of Cancer Research, London
| | - M Hills
- Academic Department of Biochemistry, Royal Marsden Hospital, London
| | - J Salter
- Breast Cancer Unit, Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France
| | - I E Smith
- Clinical Trials and Statistics Unit, The Institute of Cancer Research, London; Breast Unit
| | | | - M Dowsett
- Breast Cancer Unit, Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France; NE Thames Regional Genetics Laboratory, Great Ormond Street Hospital, London.
| |
Collapse
|
9
|
Zabaglo L, Stoss O, Rüschoff J, Zielinski D, Salter J, Arfi M, Bradbury I, Dafni U, Piccart-Gebhart M, Procter M, Dowsett M. HER2 staining intensity in HER2-positive disease: relationship with FISH amplification and clinical outcome in the HERA trial of adjuvant trastuzumab. Ann Oncol 2013; 24:2761-6. [PMID: 23894039 DOI: 10.1093/annonc/mdt275] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND Trastuzumab treatment improves survival of HER2-positive primary breast cancer. HER2 staining intensity varies widely in HER2-positive tumours. PATIENTS AND METHODS We investigated whether differences in immunohistochemical (IHC) staining intensity for HER2 in HER2-positive tumors (IHC 3+ or FISH ratio ≥2.0) was associated with prognosis or benefit from trastuzumab treatment in patients randomized to 1 year or no trastuzumab in the HERceptin Adjuvant (HERA) trial. Median follow-up was 2 years. The nested case-control analysis, included 425 patients (cases) with a disease-free survival (DFS) event and two matched controls (no DFS event) per case. Tissue sections stained for HER2 were assessed for HER2 staining intensity by image analysis. RESULTS HER2 staining intensity varied widely and correlated with HER2 gene copy number (Spearman, r = 0.498, P < 0.001) or less closely with HER2/CEP17 FISH ratio (r = 0.396, P < 0.001). We found no significant difference in DFS in the observation arm according to staining intensity (odds ratio [OR] change per 10 unit change in intensity: 1.015, 95% confidence interval [CI] 0.930-1.108) and no impact of staining intensity on benefit derived from 1-year trastuzumab (OR: 1.017, 95% CI 0.925-1.120). CONCLUSIONS Variability in HER2 staining in HER2-positive tumours has no role in clinical management with adjuvant trastuzumab. HERA TRIAL NO NCT00045032.
Collapse
Affiliation(s)
- L Zabaglo
- Academic Department of Biochemistry, Royal Marsden NHS Trust, London
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Weigel MT, Banerjee S, Arnedos M, Salter J, A'Hern R, Dowsett M, Martin LA. Enhanced expression of the PDGFR/Abl signaling pathway in aromatase inhibitor-resistant breast cancer. Ann Oncol 2012; 24:126-33. [PMID: 22865780 DOI: 10.1093/annonc/mds240] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
BACKGROUND We have found that the platelet-derived growth factor receptor (PDGFR)/Abl signaling pathway is up-regulated as a determinant of the acquisition of resistance to estrogen deprivation in vitro. We aimed to determine its clinical relevance in aromatase inhibitor (AI)-resistant breast cancer. PATIENTS AND METHODS We identified a cohort of 45 patients with estrogen receptor-positive breast cancer who had been treated with an AI, subsequently relapsed and had biopsy material available from both the presentation and post-AI recurrent lesion. PDGFRα, PDGFRβ and Abl expression was assessed in formalin-fixed paraffin-embedded sections. RESULTS Tumor protein expression of PDGFRα (1.39-fold, P=0.0065), PDGFRβ (4.32-fold, P=0.006) and Abl (1.8-fold, P=0.001) was increased at the point of relapse. Tumor and stromal expression of PDGFRα as well as PDGFRβ was significantly correlated in pre-treatment and relapse samples. High post-treatment tumor and stromal PDGFRβ levels were associated with a short time to treatment failure (TTF). Expression of PDGFRα in relapsing tumor specimens was correlated with Abl expression and Ki67 levels. Furthermore, changes in Abl correlated significantly with changes in ER expression. CONCLUSIONS These clinical data support a role for enhanced PDGF/Abl signaling in AI-resistant disease and provide a rationale for targeting the pathway in endocrine-resistant breast cancer.
Collapse
Affiliation(s)
- M T Weigel
- The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
| | | | | | | | | | | | | |
Collapse
|
11
|
Dowsett M, Afentakis M, Pineda S, Salter J, Howell A, Buzdar A, Forbes JF, Cuzick J. P2-12-01: Immunohistochemical (IHC) BAG1 Expression Improves the Estimation of Residual Risk (RR) by IHC4 in Postmenopausal Patients Treated with Anastrozole or Tamoxifen: A TransATAC Study. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-p2-12-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Aim: To determine whether the incorporation of BAG1 staining improves the estimate of RR after endocrine therapy in postmenopausal patients with ER+ve tumours treated with endocrine therapy. Background: BAG1 encodes a protein (BCL2-associated athanogene 1) that binds to BCL2 and enhances its anti-apoptotic effects. BAG1 is included as a separate subgroup in the 21-gene OncotypeDx Recurrence Score (RS) that is used to assess RR after endocrine therapy in primary ER+ breast cancer. IHC4 is a 4-panel set of IHC markers (ER, PgR, HER2, Ki67) that was shown to provide as much prognostic accuracy as RS in the translational arm of the ATAC trial (TransATAC) of anastrozole versus tamoxifen alone or combined and subsequently independently validated (Cuzick et al, JCO, 2011, in press). Addition of extra markers such as BAG1 to IHC4 may improve the accuracy of the IHC4 and provide extra discriminatory power for oncologists.
Methods: Samples in triplicate TMAs from the TransATAC cohort were stained for BAG1 using the Genetex 3.10G3E2 antibody after validation using siRNA knockdown. Staining was scored separately as nuclear or cytoplasmic and categorized by intensity as 0, 1, 2 or 3. BAG1 IHC values were assessed for their correlation with BAG1 mRNA levels. The statistical analysis plan was pre-specified and tested possible additional information from BAG1 expression to the IHC4 in patients not treated with chemotherapy by change in the likelihood ratio chi-square (ΔLR-X2). Results were included only if there was also complete data for ER, PgR, Ki67 and HER2. Primary analysis was on the HER2−ve node-negative (N-neg) population; secondary analysis was on all N-neg patients. Follow-up was to 10 years and the primary end-point was time to distant recurrence (TTDR).
Results: Data on both nuclear and cytoplasmic BAG1 as well as the other 4 IHC parameters was available on 961 cases of which 855 were HER2−ve. There was a significant correlation between cytoplasmic and nuclear BAG1 (p=0.23, p<0.0001) but the nuclear staining correlated better with mRNA levels and was therefore considered further. Weak but significant correlations were also seen with ER, PgR and tumour grade. In the univariate analysis nuclear BAG1 was significantly associated with worse TTDR in HER2−ve and all N-neg cases (X2=7.91, p=0.005 and X2=10.63, p=0.001 respectively). Nuclear BAG1 also contributed significantly in multivariate analyses in the 2 populations firstly when added to the clinical model (X2=4.99, p=0.02 and X2=5.93, p=0.015 respectively) and secondly when subtracted from clinical plus the IHC4 parameters (X2=5.55, p=0.02 and X2=4.50, p=0.03 respectively).
Conclusions: Nuclear BAG1 expression has significant value for estimating RR that is independent of standard clinical and IHC parameters and it improves the prediction of TTDR in the TransATAC population beyond that with the validated IHC4 score. Unlike IHC4 markers, BAG1 is not commonly measured in pathology work-up of breast cancers. The clinical utility of its addition to IHC4 will be tested by measuring its discrimination of high and low risk patients in clinical practice.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P2-12-01.
Collapse
Affiliation(s)
- M Dowsett
- 1Royal Marsden Hospital, London, United Kingdom; Wolfson Institute of Preventive Medicine, London, United Kingdom; Christie Hospital, Manchester, United Kingdom; MD Anderson Cancer Center, Houston; University of Newcastle, Newcastle, Australia
| | - M Afentakis
- 1Royal Marsden Hospital, London, United Kingdom; Wolfson Institute of Preventive Medicine, London, United Kingdom; Christie Hospital, Manchester, United Kingdom; MD Anderson Cancer Center, Houston; University of Newcastle, Newcastle, Australia
| | - S Pineda
- 1Royal Marsden Hospital, London, United Kingdom; Wolfson Institute of Preventive Medicine, London, United Kingdom; Christie Hospital, Manchester, United Kingdom; MD Anderson Cancer Center, Houston; University of Newcastle, Newcastle, Australia
| | - J Salter
- 1Royal Marsden Hospital, London, United Kingdom; Wolfson Institute of Preventive Medicine, London, United Kingdom; Christie Hospital, Manchester, United Kingdom; MD Anderson Cancer Center, Houston; University of Newcastle, Newcastle, Australia
| | - A Howell
- 1Royal Marsden Hospital, London, United Kingdom; Wolfson Institute of Preventive Medicine, London, United Kingdom; Christie Hospital, Manchester, United Kingdom; MD Anderson Cancer Center, Houston; University of Newcastle, Newcastle, Australia
| | - A Buzdar
- 1Royal Marsden Hospital, London, United Kingdom; Wolfson Institute of Preventive Medicine, London, United Kingdom; Christie Hospital, Manchester, United Kingdom; MD Anderson Cancer Center, Houston; University of Newcastle, Newcastle, Australia
| | - JF Forbes
- 1Royal Marsden Hospital, London, United Kingdom; Wolfson Institute of Preventive Medicine, London, United Kingdom; Christie Hospital, Manchester, United Kingdom; MD Anderson Cancer Center, Houston; University of Newcastle, Newcastle, Australia
| | - J Cuzick
- 1Royal Marsden Hospital, London, United Kingdom; Wolfson Institute of Preventive Medicine, London, United Kingdom; Christie Hospital, Manchester, United Kingdom; MD Anderson Cancer Center, Houston; University of Newcastle, Newcastle, Australia
| |
Collapse
|
12
|
Drury SC, Detre S, Leary A, Salter J, Reis-Filho J, Barbashina V, Marchio C, Lopez-Knowles E, Ghazoui Z, Habben K, Arbogast S, Johnston S, Dowsett M. Changes in breast cancer biomarkers in the IGF1R/PI3K pathway in recurrent breast cancer after tamoxifen treatment. Endocr Relat Cancer 2011; 18:565-77. [PMID: 21734071 DOI: 10.1530/erc-10-0046] [Citation(s) in RCA: 70] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
Development of resistance to the antioestrogen tamoxifen occurs in a large proportion of patients with oestrogen receptor-positive (ER+) breast cancer and is an important clinical challenge. While loss of ER occurs in c.20% of tamoxifen-resistant tumours, this cannot be the sole explanation for tamoxifen treatment failure. PI3K pathway activation, including by insulin-like growth factor receptor 1 (IGF1R), has been implicated in some resistance models. The primary aim was to determine whether evidence exists in clinical breast cancer for a role of IGF1R and/or the PI3K pathway, in acquisition of resistance to tamoxifen. Invasive primary and recurrent tamoxifen-resistant tumours from the same patient (n=77) were assessed for changes in ER, progesterone receptor (PgR), human epidermal growth factor receptor 2 (HER2), IGF1R, stathmin, PTEN expression and PIK3CA mutations where possible. ER and PgR levels were significantly reduced at recurrence with 22 and 45%, respectively, showing negative status at this time. Acquisition of HER2 overexpression occurred in 6% of cases. IGF1R expression was significantly reduced in both ER+ and ER- recurrences and stathmin levels increased. A positive association between stathmin and IGF1R emerged in recurrent samples, despite their opposing relationships with ER, suggesting some coalescence of their activities may be acquired. The data confirm loss of ER and PgR and gain of HER2 in some tamoxifen-resistant tumours. There is no evidence for IGF1R gain in tamoxifen resistance; increases in stathmin levels suggest that activation of the PI3K pathway may have contributed, but PTEN loss and PIK3CA hotspot mutations were relatively rare.
Collapse
Affiliation(s)
- S C Drury
- Translational Research, The Breakthrough Breast Cancer Research Centre, London, UK.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Balko JM, Cook RS, Miller TW, Bhola NE, Sanders M, Granja-Ingram NM, Sanchez V, Meszoely IM, Salter J, Dowsett M, Stemke-Hale K, Gonzalez-Angulo AM, Mills GB, Arteaga CL. Use of gene expression patterns post neoadjuvant chemotherapy to identify a role for the MAPK phosphatase DUSP4 in therapeutic resistance and a stem-like phenotype in basal-like breast cancer (BLBC). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.10509] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
14
|
Balko JM, Sanders ME, Granja-Ingram NM, Sanchez V, Meszoely IM, Salter J, Dowsett M, Arteaga CL. Abstract P6-04-05: Digital Quantification of Post-Neoadjuvant Chemotherapy Breast Tumor RNA Reveals a Basal-Derived Gene Signature Associated with Post-Treatment Ki67. Cancer Res 2010. [DOI: 10.1158/0008-5472.sabcs10-p6-04-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Neoadjuvant chemotherapy (NAC) leads to a pathological complete response (pCR) in -20% of patients with breast cancer. The rest of the patients exhibit residual disease (RD) in the breast after NAC and are more likely to have a metastatic recurrence. Recent data show that tumor cell proliferation, as measured by Ki67 in the residual post-NAC cancer, can inform clinical outcome. We hypothesized that RD after NAC will harbor different gene expression as a function of Ki67 index. A 2nd hypothesis is that identification of key alterations in tumors with post-NAC high Ki67 will identify molecules or networks that can be therapeutically targeted in the immediate post-operative setting to eradicate clinically silent micro-metastases.
We utilized Nanostring digital RNA quantification to measure the expression of 350 genes in 49 post-NAC residual breast cancers. The cohort was enriched for triple-negative cancers (24/49). Genes were selected based on relevance to breast cancer, published prognostic signatures, and our own unsupervised class discovery approach from existing microarray data. For the selected gene sets, we included a chemo-resistance signature (CHEMO), a stroma signature (STROMA), and a WNT/metastasis signature (WNT/MET). For the unsupervised analysis, publicly available pre-treatment microarray data from chemotherapy-treated ER-breastcancers that did not achieve pCR were clustered and the two most prominent groups were used to select a 250 gene set (CLUSTER). Ki67 was assessed in the RD for the 49 tumors and correlated to absolute RNA counts of the 350 selected genes.
Ki67 was strongly associated with subtype as defined by the PAM50 classifier (P<0.0001). Basal tumors demonstrated the highest Ki67, followed by Luminal B, HER2, and Luminal A tumors (median = 63.5, 27, 22.6, and 5.5%, respectively). The CHEMO signature correlated inversely with Ki67 index (p=2.5e-8): paradoxically, genes positively associated with a higher probability of pCR correlated with a high Ki67 in the post-NAC specimens. Thus, chemotherapy-enriched tumors demonstrate distinct and unexpected gene expression patterns after treatment. The WNT/MET and STROMA gene sets showed significant trends with similar directionality to the CHEMO gene set. Our CLUSTER gene set was highly predictive of Ki67 (p=3.6e-6) and robustly associated with basal subtype (p=2.6e-13). MELK, an anti-apoptotic kinase involved in activation of Bcl-G was positively associated with a high Ki67 independently of tumor subtype (p=0.035 and p=0.045 in luminal and basal, respectively). In luminal tumors, high expression of BRCA1, BRCA2, and RRM2 was associated with high Ki67 (p=0.027, 0.016, and 7e-5, respectively), while reduced DUSP4 expression, a MAPK phosphatase, was predictive of high Ki67 in basal post-NAC tumors (p=6e-4).
Existing gene expression predictors built on pre-treatment data did not match expected patterns in chemotherapy-enriched tumors. Breast cancer subtype was strongly associated with a chemotherapy-refractory high Ki67 index in the surgically removed tumors. Further, the assessment of gene expression patterns in RD may be important in ascertaining the molecular underpinnings of aggressive disease. Thus, our defined gene signature may offer insights into molecular targets in patients who do not achieve pCR after NAC.
Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P6-04-05.
Collapse
Affiliation(s)
- JM Balko
- Vanderbilt University; Institute of Cancer Research, London, UK; Royal Marsden Hospital, London, UK
| | - ME Sanders
- Vanderbilt University; Institute of Cancer Research, London, UK; Royal Marsden Hospital, London, UK
| | - NM Granja-Ingram
- Vanderbilt University; Institute of Cancer Research, London, UK; Royal Marsden Hospital, London, UK
| | - V Sanchez
- Vanderbilt University; Institute of Cancer Research, London, UK; Royal Marsden Hospital, London, UK
| | - IM Meszoely
- Vanderbilt University; Institute of Cancer Research, London, UK; Royal Marsden Hospital, London, UK
| | - J Salter
- Vanderbilt University; Institute of Cancer Research, London, UK; Royal Marsden Hospital, London, UK
| | - M Dowsett
- Vanderbilt University; Institute of Cancer Research, London, UK; Royal Marsden Hospital, London, UK
| | - CL. Arteaga
- Vanderbilt University; Institute of Cancer Research, London, UK; Royal Marsden Hospital, London, UK
| |
Collapse
|
15
|
Arnedos M, Drury S, Afentakis M, Hills M, Salter J, Smith IE, Dowsett M. Biomarker changes associated with the development of resistance to aromatase inhibitors (AIs) in ER-positive breast cancer. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.1034] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
16
|
Carter M, Baxter B, Bushnell D, Cockerill S, Chapman J, Fram S, Goulding E, Lockyer M, Mathews N, Najarro P, Rupassara D, Salter J, Thomas E, Wheelhouse C, Borger J, Powell K. Diphenylcarboxamides as Inhibitors of HCV Non-Structural Protein NS5a. Antiviral Res 2010. [DOI: 10.1016/j.antiviral.2010.02.331] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
17
|
Pinhel I, MacNeill F, Hills M, Detre S, Salter J, Smith I, Dowsett M. 397 Extreme loss of immunoreactive phosphoproteins during routine fixation of primary breast cancer. EJC Suppl 2010. [DOI: 10.1016/s1359-6349(10)70423-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
18
|
Zabaglo L, Zabaglo L, Salter J, Salter J, Anderson H, Anderson H, Hills M, A'Hern R, Dowsett M, Dowsett M. Comparative Validation of the SP6 and MIB1 Antibodies to Ki67 and Their Use in Tissue Microarray (TMA) and Image Analysis for Breast Cancer. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-09-3048] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Aim: To compare SP6 and MIB1 antibodies against Ki67 for use with visual scoring, image analysis and TMA (tissue microarray) analysis.Background: Immunohistochemical detection of Ki67 has been widely used in assessing the proliferation fraction in breast cancer. Neoadjuvant studies revealed that changes in Ki67 predict benefit from endocrine treatment, and that on-treatment Ki67 measurements are better predictors of long-term outcome than pretreatment levels (Dowsett at al, JNCI 2007; 99:167-170). As a result Ki67 is the primary end-point for some pre-surgical trials. MIB-1 has been the preferred Ki67 antibody for over 10 years. A rabbit monoclonal antibody, SP6, has become available with apparently improved performance, e.g. reduced background non-nuclear staining. The importance of Ki67 led us to conduct a systematic series of studies to validate SP6 in comparison to MIB1.Methods: We used TMAs constructed from (i) 177 archival FFPE blocks of primary or locally recurrent breast tumours from women treated with an aromatase inhibitor (AI) for advanced disease (AI TMAs) and (ii) one set of replicate blocks (200 tumours) from the TransATAC program. The TMAs were of 600µm cores. Three replicate TMAs (A, B, C) were used. Staining was performed using DAKO Autostainer and DAKO REAL Kit Detection System. MIB-1 antibody (DAKO) was used at a dilution of 1:40, whereas 1:100 dilution was used for SP6 antibody (Abcam). Stained sections were examined either visually or using the Ariol image analysis system (Genetix Ltd.).Results: There was a strong correlation between the antibodies in AI TMAs scored manually (n=161, r=0.93, p<0.0001). Coefficient of variation was calculated in all cases with ≥2 available cores. MIB1 showed higher median CV [%] compared with SP6 (43.7 vs. 36.7, respectively) in AI TMAs, but a lower CV in TransATAC TMAs (42.0 vs. 51.4, respectively). In a univariate analysis of manual scores from AI TMAs there was a similar association of Ki67 with time to treatment failure (TTF) with the two antibodies (HR: 1.15; 95% CI: 1.00-1.33; p=0.052 and HR: 1.19; 95% CI: 1.00-1.43; p=0.045 for MIB1 and SP6 respectively). Correlation between manual and image analysis scores was markedly better with the SP6 antibody (r=0.71 and r=0.88 for MIB1 and SP6, respectively).Conclusions: SP6 and MIB1 provide highly comparable measures of Ki67 that predict progression of advanced disease similarly. SP6 is substantially better suited than MIB1 to image analysis, and is now our preferred antibody for future studies.Funded by Breakthrough Breast Cancer and The Mary-Jean Mitchell Green Foundation.
Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 3048.
Collapse
Affiliation(s)
| | - L. Zabaglo
- 2Breakthrough Breast Cancer Research Centre, United Kingdom
| | - J. Salter
- 1Royal Marsden Hospital, United Kingdom
| | - J. Salter
- 2Breakthrough Breast Cancer Research Centre, United Kingdom
| | | | - H. Anderson
- 2Breakthrough Breast Cancer Research Centre, United Kingdom
| | - M. Hills
- 1Royal Marsden Hospital, United Kingdom
| | - R. A'Hern
- 3Institute of Cancer Research, United Kingdom
| | | | - M. Dowsett
- 2Breakthrough Breast Cancer Research Centre, United Kingdom
| |
Collapse
|
19
|
Pinhel I, Pinhel I, Hills M, Drury S, Drury S, Salter J, Salter J, Johnson L, Barrett-Lee P, Harris A, Dowsett M. ER and HER2 Expression Are POSITIVELY Correlated in HER2 Non-Over Expressing Breast Cancer. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-09-703] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Aim: To determine the relationship between ER and HER2 expression according to HER2 amplification status.Background: ER and HER2 are the most commonly measured biomarkers in breast cancer and are important targets for therapy. It is known that ER and HER2 positivity are inversely correlated and that among ER+ tumours ER expression is higher in HER2 non-overexpressing (−ve) than HER2 overexpressing (+ve) disease (Konecny et al, JNCI 2003, 95: 142-53). There are however, very few data on the quantitative relationship between ER and HER2 expression in HER2−ve tumours. We therefore measured the expression of ER and HER2 at both the mRNA and protein level in HER2 +ve and −ve breast carcinomas.Methods: ER and HER2 levels were assessed by IHC (6F11 antibody and HercepTest, respectively) on tissue microarrays and q-RT-PCR in formalin-fixed primary breast cancers from 429 patients in the tamoxifen arm of the ABC Trial (ABC Trialists, JNCI 2007, 99: 506-15). HER2 amplification status was assessed with the PathVysion 2-probe FISH test. ER IHC was H-scored. Transcript levels for ER and HER2 from 1139 HER2−ve TransATAC tumours were available from the Oncotype DX test (Dowsett et al, Cancer Res 2009, 69suppl: 75s).Results: Matched results were available from all analyses for 257 ABC patients except for 25 cases where HER2 was by IHC or FISH. HER2 was amplified in 14.4% and equivocal in 1.3% of cases. ER was +ve in 67% of cases. The expected negative correlation between levels of ER and HER2 expression was found in HER2 +ve tumours (r=-0.45, p=0.0028). In contrast in HER2-ve tumours (ER+ve and ER-ve combined) there was a significant POSITIVE correlation between ER and HER2 mRNA levels (r=0.43, p<0.0001). As a result in HER2−ve tumours the quantitative level of HER2 was higher in ER+ve than ER−ve tumours (mean fold difference 1.74, p<0.0001). There was a mean 5.8-fold higher HER2 transcript levels in HER2+ve vs HER2−ve tumours in ER+ve disease and 12.9-fold higher in ER−ve disease. The positive correlation though weaker was maintained in the ER+ve HER2−ve group (r=0.24, p=0.0023) and was present to a similar extent in that subgroup in TransATAC (r=0.25, p<0.00001). The positive association was also significant in ER IHC analyses in ABC: mean±95%CI H-scores were 90±19 and 134±19 in the 0 and 1+ HER2 IHC categories, respectively (p=0.0013).Conclusions: ER and HER2 expression are positively correlated at both protein and transcript levels in HER2−ve breast cancer in contrast to their negative correlation in HER2+ve disease. The distinction between HER2+ve and HER2−ve is greater in ER−ve than ER+ve disease and this may lead to greater diagnostic uncertainties in ER+ve patients. These findings may also have importance for signaling pathways and application of targeted therapy in HER2−ve disease.*Acknowledgement: We are grateful to the ABC Trial Working and Biological Studies Groups, the ATAC Trialists and Cancer Research UK for funding.
Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 703.
Collapse
Affiliation(s)
- I. Pinhel
- 1The Institute of Cancer Research, United Kingdom
| | - I. Pinhel
- 2The Royal Marsden Hospital, United Kingdom
| | - M. Hills
- 2The Royal Marsden Hospital, United Kingdom
| | - S. Drury
- 2The Royal Marsden Hospital, United Kingdom
| | - S. Drury
- 3Breakthrough Breast Cancer Research Centre, United Kingdom
| | - J. Salter
- 2The Royal Marsden Hospital, United Kingdom
| | - J. Salter
- 3Breakthrough Breast Cancer Research Centre, United Kingdom
| | - L. Johnson
- 1The Institute of Cancer Research, United Kingdom
| | | | - A. Harris
- 5John Radcliffe Hospital, United Kingdom
| | - M. Dowsett
- 2The Royal Marsden Hospital, United Kingdom
| | | |
Collapse
|
20
|
Drury S, Drury S, Johnson N, Hills M, Salter J, Salter J, Afentakis M, Dunbier A, Dunbier A, Folkerd E, Peto J, Peto J, Fletcher O, Dowsett M, Dowsett M, FACE Trialists .. A Breast Cancer-Associated SNP Adjacent to ESR1 Correlates with Oestrogen Receptor-α (ERα) Level in Invasive Breast Tumours. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-09-4138] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Aim: To identify whether breast cancer-associated SNP rs2046210 is associated with ERα level in invasive breast tumours.BackgroundA recent genome-wide association study identified SNP rs2046210 at 6q25.1 as having a strong association with breast cancer risk1. The SNP is located 29kb upstream of the first untranslated exon of ESR1 and 180kb upstream of the transcription start site2. Rs2046210 is not in linkage disequilibrium (LD) with two of the most widely studied polymorphisms in ESR1. We test here the hypothesis that rs2046210 may be associated with altered ESR1 expression.MethodsPatients with both leukocyte DNA and invasive breast tumour paraffin blocks available were identified from two of our ongoing tissue collections: Femara Anastrazole Clinical Evaluation (FACE) and the British Breast Cancer (BBC) study. Germline DNA was extracted from bloods using the QIAamp DNA Blood Mini Kit. PCR was performed with primers spanning the SNP site, with a single basepair mismatch in the reverse sequence to generate an HhaI restriction site in the presence of the C allele. PCR product was run on a 3% agarose gel to confirm presence of a single 120bp band. Restriction digest with HhaI was then performed and products run on a 4% Metaphor agarose gel. Genotype was assigned as follows: 97bp band only = wild-type (C/C); 97bp and 120bp band = heterozygote (C/T); 120bp band only = variant (T/T). From corresponding invasive breast tumour, ERα was assessed on 4μm whole sections using clone 6F11 (Vector Labs) and quantified by H-score. Mean H-scores (left and right invasive breast tumours) were used for the BBC group. ERα- samples (H-score≤1.0) were excluded. Analysis was by ANOVA using non-parametric bias-corrected and accelerated 95% bootstrap confidence intervals (2000 replications), with genotype fitted as a score and study as a stratifying co-variate.ResultsH-score (mean) by genotypeStudyWild-typeHeterozygoteVariantFACE (n=280)171.8180.9184.9BBC (n=46)180.0178.9194.1Fitted mean172.6179.7186.7(% samples)(45)(44)(11) Minor allele frequency was 33%, which is similar to the 38% previously reported in patients of European ancestry1. Within FACE, increased ERα was seen with presence of variant SNP. In the BBC group, variant SNP patients had higher ERα than both wild-type and heterozygote. Overall, there was a significant difference in ERα score per genotype group of 7.05, (95% CI 0.7-13.5, p=0.035). This was circa 4% difference in H-score per variant allele.ConclusionThe variant genotype of SNP rs2046210 is associated with increased ERα expression. While the increase contributed by the variant allele is relatively modest, this may partly explain why the SNP is associated with increased breast cancer risk. Similar studies should be conducted in normal breast tissue.1Zheng et al. (2009) Nat. Gen. 41(3): 324-3282Kos et al. (2001) Mol. Endocrinol. 15: 2057-2063
Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 4138.
Collapse
Affiliation(s)
- S. Drury
- 1Breakthrough Breast Cancer Research Centre, United Kingdom
| | - S. Drury
- 2Royal Marsden Hospital, United Kingdom
| | - N. Johnson
- 3Breakthrough Breast Cancer Research Centre, United Kingdom
| | - M. Hills
- 2Royal Marsden Hospital, United Kingdom
| | - J. Salter
- 1Breakthrough Breast Cancer Research Centre, United Kingdom
| | - J. Salter
- 2Royal Marsden Hospital, United Kingdom
| | | | - A. Dunbier
- 1Breakthrough Breast Cancer Research Centre, United Kingdom
| | | | | | | | - J. Peto
- 5Institute of Cancer Research, Surrey, United Kingdom
| | - O. Fletcher
- 3Breakthrough Breast Cancer Research Centre, United Kingdom
| | - M. Dowsett
- 1Breakthrough Breast Cancer Research Centre, United Kingdom
| | | | | |
Collapse
|
21
|
Dowsett M, Dunbier A, Anderson H, Salter J, Detre S, Jones R, Skene A, Dixon M, Smith IE. Biomarkers and predictive factors of response to neoadjuvant treatment. Breast Cancer Res 2009. [PMCID: PMC4284875 DOI: 10.1186/bcr2272] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
22
|
Sharathkumar A, Hardesty B, Greist A, Salter J, Kerlin B, Heiman M, Sulkin M, Shapiro A. Variability in bleeding phenotype in Amish carriers of haemophilia B with the 31008 C-->T mutation. Haemophilia 2008; 15:91-100. [PMID: 18721150 DOI: 10.1111/j.1365-2516.2008.01792.x] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
Abstract
The aim of this study was to characterize the variability of bleeding phenotype and its association with plasma factor IX coagulant activity (FIX:C) in haemophilia B carriers in a large Amish pedigree with a unifying genetic mutation, C-to-T transition at base 31008 of the factor IX gene (Xq27.1-27.2). A cross-sectional survey of haemophilia B carriers included a multiple choice questionnaire evaluating symptoms of mucocutaneous bleeding, joint bleeding and bleeding after haemostatic stress [menstruation, postpartum haemorrhage (PPH), dental extractions and invasive surgeries]. Severity of bleeding was graded as 0 to 4, 0 being no bleeding whereas 4 being severe bleeding. Association between total bleeding scores and the FIX:C was evaluated. Sixty-four haemophilia B carriers participated in this study. Median age: 18 years (range 1-70 years); median bleeding score: 1 (range 0-8). Besides PPH, isolated symptoms of bruising, epistaxis, menorrhagia and postsurgical bleeding including dental extraction were not associated with lower FIX:C. Bleeding score >/=3 was associated with involvement of at least two bleeding sites and a lower mean FIX:C of 42 +/- 10.3% (95% CI 36.4-47.7) while a score >3 had involvement of </=2 sites and higher mean FIX:C of 54.9 +/- 21.5% (95% CI 49-61), P = 0.005. Subcutaneous haematoma formation and bleeding after haemostatic stress requiring treatment were associated with bleeding scores >/=3. Phenotypic variability existed among the carriers of haemophilia B who belonged to a single pedigree carrying a single unifying mutation. The utility of bleeding scores to define bleeding phenotype precisely in haemophilia B carriers needs further evaluation.
Collapse
Affiliation(s)
- A Sharathkumar
- Indiana Hemophilia and Thrombosis Center, Indianapolis, IN, USA
| | | | | | | | | | | | | | | |
Collapse
|
23
|
Quinn E, Salter J, Hills M, Dowsett M. Concordance between tissue microarray and whole tissue sections for ER expression and PgR and HER-2 status: a pilot study for the Trans-ATAC trial. EJC Suppl 2008. [DOI: 10.1016/s1359-6349(08)70627-x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
24
|
Thumshirn M, Fruehauf H, Stutz B, Tougas G, Salter J, Fried M. Clinical trial: effects of tegaserod on gastric motor and sensory function in patients with functional dyspepsia. Aliment Pharmacol Ther 2007; 26:1399-407. [PMID: 17892526 DOI: 10.1111/j.1365-2036.2007.03521.x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
BACKGROUND Tegaserod, a serotonin receptor type-4 partial agonist, stimulates gastrointestinal motility and has been shown to increase gastric volumes before and after a meal in healthy volunteers. Its effect on gastric motor and sensory function in patients with functional dyspepsia is unclear. AIM To evaluate the effects of tegaserod on gastric compliance, accommodation and gastric sensory function in patients with functional dyspepsia and healthy volunteers. METHODS Sixteen patients with functional dyspepsia and 12 healthy volunteers were studied on two occasions, each after a 7-day treatment with either placebo or tegaserod 6 mg b.d. using a double-blind, randomized, crossover design. After each treatment period a gastric barostat study was performed fasting and during intraduodenal lipid infusion. RESULTS Tegaserod increased postprandial gastric compliance in functional dyspepsia patients (P = 0.04). Healthy volunteers showed enhanced postprandial gastric compliance after placebo (P = 0.03). Between-treatment analysis of gastric accommodation revealed a significant increase in intrabag volumes after tegaserod in healthy volunteer (P = 0.04); no difference could be seen in functional dyspepsia patients. Tegaserod had no effect on gastric sensation. CONCLUSIONS Tegaserod enhances postprandial gastric compliance in functional dyspepsia patients and gastric accommodation in healthy volunteers. The improvement of proximal gastric motor function suggests a beneficial role of tegaserod in patients with functional dyspepsia.
Collapse
Affiliation(s)
- M Thumshirn
- Division of Gastroenterology and Hepatology, University Hospital Zurich, Zurich, Switzerland.
| | | | | | | | | | | |
Collapse
|
25
|
Jones RL, Salter J, Nerurkar A, Parton M, A’Hern R, Smith IE, Dowsett M. Prognostic (Px) significance of Ki67 before and after neoadjuvant chemotherapy (CT) in early breast cancer. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.573] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
573 Background: High levels of the proliferation marker Ki67 are associated with a higher response rate to CT but poorer long-term outcome. The Px significance of Ki67 before CT and at surgical excision was compared. Methods: 103 patients treated with CT with pre- and post- (excision) CT tissue and a further 181 with only excision tissue available were identified, 37 and 76 of these respectively were ER+ and also received tamoxifen. The following factors were considered pre-CT and at excision (where relevant) for their relationship with relapse-free (RFS) and overall (OS) survival: ER, PR, HER2, grade, Ki67, histological type, vascular invasion, age/menses, T and N stage, pre-therapy operability, clinical response, CT regimen, type of surgery, adjuvant therapy, pathological tumour size and nodal involvement. Results: In the paired cohort univariate analysis of RFS the following factors were associated with poorer Px (a) pre-CT: ER- (p=0.003); increasing T stage (p<0.001), N stage (p=0.002) and Ki67 (p<0.001); (b) at excision: increasing grade (p=0.01), tumour size (p=0.02), nodal status (p<0.001) and Ki67 (p<0.001); no adjuvant endocrine therapy (p<0.001). On multivariate analysis only excision Ki67 (p<0.001) was significant although there was a suggestion pre-therapy Ki67 was important (p<0.10). On univariate analysis of OS the following factors associated with poorer Px (a) pre-CT: ER- (p=0.006); increasing T stage (p<0.001) and Ki67 (p<0.001); (b) at excision: increasing grade (p=0.04), tumour size (p=0.005), nodal status (p<0.03) and Ki67 (p<0.001); no adjuvant endocrine therapy (p=0.001). On multivariate analysis both pre-CT and excision Ki67 were significant independent predictors but the latter was more highly significant. (p<0.02 + p<0.0001, respectively) Assessing the combined group of 284 patients, after 5 years the highest and lowest tertiles of excision Ki67 had strikingly different Px: RFS 36% and 73%; OS 50% and 85%, respectively. Conclusions: Ki67 after CT is a strong predictor of long-term outcome. The greater significance of Ki67 in the excision sample may be due to this identifying patients in whom residual highly proliferative disease remains after CT. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- R. L. Jones
- Royal Marsden Hospital, London, United Kingdom
| | - J. Salter
- Royal Marsden Hospital, London, United Kingdom
| | - A. Nerurkar
- Royal Marsden Hospital, London, United Kingdom
| | - M. Parton
- Royal Marsden Hospital, London, United Kingdom
| | - R. A’Hern
- Royal Marsden Hospital, London, United Kingdom
| | - I. E. Smith
- Royal Marsden Hospital, London, United Kingdom
| | - M. Dowsett
- Royal Marsden Hospital, London, United Kingdom
| |
Collapse
|
26
|
Pierga JY, Reis-Filho JS, Cleator SJ, Dexter T, MacKay A, Simpson P, Fenwick K, Iravani M, Salter J, Hills M, Jones C, Ashworth A, Smith IE, Powles T, Dowsett M. Microarray-based comparative genomic hybridisation of breast cancer patients receiving neoadjuvant chemotherapy. Br J Cancer 2007; 96:341-51. [PMID: 17133270 PMCID: PMC2359992 DOI: 10.1038/sj.bjc.6603483] [Citation(s) in RCA: 42] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2006] [Revised: 10/12/2006] [Accepted: 10/23/2006] [Indexed: 12/29/2022] Open
Abstract
We analysed the molecular genetic profiles of breast cancer samples before and after neoadjuvant chemotherapy with combination doxorubicin and cyclophosphamide (AC). DNA was obtained from microdissected frozen breast core biopsies from 44 patients before chemotherapy. Additional samples were obtained before the second course of chemotherapy (D21) and after the completion of the treatment (surgical specimens) in 17 and 21 patients, respectively. Microarray-based comparative genome hybridisation was performed using a platform containing approximately 5800 bacterial artificial chromosome clones (genome-wide resolution: 0.9 Mb). Analysis of the 44 pretreatment biopsies revealed that losses of 4p, 4q, 5q, 12q13.11-12q13.12, 17p11.2 and 17q11.2; and gains of 1p, 2p, 7q, 9p, 11q, 19p and 19q were significantly associated with oestrogen receptor negativity. 16q21-q22.1 losses were associated with lobular and 8q24 gains with ductal types. Losses of 5q33.3-q4 and 18p11.31 and gains of 6p25.1-p25.2 and Xp11.4 were associated with HER2 amplification. No correlations between DNA copy number changes and clinical response to AC were found. Microarray-based comparative genome hybridisation analysis of matched pretreatment and D21 biopsies failed to identify statistically significant differences, whereas a comparison between matched pretreatment and surgical samples revealed a statistically significant acquired copy number gain on 11p15.2-11p15.5. The modest chemotherapy-driven genomic changes, despite profound loss of cell numbers, suggest that there is little therapeutic selection of resistant non-modal cell lineages.
Collapse
Affiliation(s)
- J-Y Pierga
- Breakthrough Breast Cancer Research Center, The Institute of Cancer Research, London, SW3 6JB, UK
- Medical Oncology Department, Institut Curie, Paris, cedex 5, France
| | - J S Reis-Filho
- Breakthrough Breast Cancer Research Center, The Institute of Cancer Research, London, SW3 6JB, UK
| | - S J Cleator
- Breakthrough Breast Cancer Research Center, The Institute of Cancer Research, London, SW3 6JB, UK
| | - T Dexter
- Breakthrough Breast Cancer Research Center, The Institute of Cancer Research, London, SW3 6JB, UK
| | - A MacKay
- Breakthrough Breast Cancer Research Center, The Institute of Cancer Research, London, SW3 6JB, UK
| | - P Simpson
- Breakthrough Breast Cancer Research Center, The Institute of Cancer Research, London, SW3 6JB, UK
| | - K Fenwick
- Breakthrough Breast Cancer Research Center, The Institute of Cancer Research, London, SW3 6JB, UK
| | - M Iravani
- Breakthrough Breast Cancer Research Center, The Institute of Cancer Research, London, SW3 6JB, UK
| | - J Salter
- Academic Department of Biochemistry, Royal Marsden Hospital NHS Trust, Fulham Road, London, SW3 6JJ, UK
| | - M Hills
- Academic Department of Biochemistry, Royal Marsden Hospital NHS Trust, Fulham Road, London, SW3 6JJ, UK
| | - C Jones
- Section of Paediatric Oncology, Institute of Cancer Research, London, SM2 5NG, UK
| | - A Ashworth
- Breakthrough Breast Cancer Research Center, The Institute of Cancer Research, London, SW3 6JB, UK
| | - I E Smith
- Breast Cancer Unit, Royal Marsden Hospital, London, SW3 6JJ, UK
| | - T Powles
- Breast Cancer Unit, Royal Marsden Hospital, London, SW3 6JJ, UK
| | - M Dowsett
- Breakthrough Breast Cancer Research Center, The Institute of Cancer Research, London, SW3 6JB, UK
- Academic Department of Biochemistry, Royal Marsden Hospital NHS Trust, Fulham Road, London, SW3 6JJ, UK
| |
Collapse
|
27
|
Dowsett M, Smith I, Skene A, Llombart A, Mayordomo J, Detre S, Salter J, Beresford E, Magill P. Biological and clinical outcomes from a phase II placebo-controlled neoadjuvant study of anastrozole alone or with gefitinib in postmenopausal women with ER/PgR+ breast cancer (Study 223). J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.515] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
515 Background: Gefitinib, an EGFR-tyrosine kinase inhibitor, reduces breast cancer cell growth and potentiates endocrine therapy in model systems. This double-blind multicentre study compared anastrozole 1 mg/day alone with anastrozole + gefitinib 250 mg/day as neoadjuvant therapy for breast cancer in a novel design aiming to assess additional benefit from gefitinib in individual patients. Methods: Postmenopausal women with stage I-IIIB breast cancer and ER and/or PgR+ tumours received anastrozole for 16 wks and were randomised (2:5:5 ratio) to: combination with gefitinib for 16 wks (AG); placebo for 2 wks then gefitinib for 14 wks (A:AG, to test for additional Ki67 suppression); placebo for 16 wks (A alone). Biopsies were taken at baseline, 2 and 16 wks. Primary comparison was change in Ki67 by 16 wks. Secondary comparison was objective tumour response rate (ORR) using UICC/WHO criteria at 16 wks. Results: 206 patients (pts) were randomised: (31 AG, 90 A:AG, 85 A alone); demography was well balanced between the groups. 109 pts were evaluable for Ki67: 59 AG + A:AG; 50 A alone. Change in Ki67 levels at 16 wks was not significantly different in those pts who received gefitinib + anastrozole versus anastrozole alone (p=0.257). The addition of gefitinib after 2 weeks of anastrozole did not further suppress Ki67 levels (p=0.164). 188 pts were evaluable for ORR (109 AG + A:AG; 79 A alone). The ORR was 48% in pts who received gefitinib + anastrozole and 61% in pts treated with anastrozole alone (p=0.067). Conclusions: Neither the biological nor the clinical activity of anastrozole was enhanced by the addition of gefitinib; although non-significant, both endpoints unexpectedly suggested a trend against the combination in this patient population. Molecular investigations of signal transduction pathways are underway to understand the significance of these findings. [Table: see text] [Table: see text]
Collapse
Affiliation(s)
- M. Dowsett
- Royal Marsden Hospital, London, United Kingdom; Royal Bournemouth Hospital, Bournemouth, United Kingdom; Hospital Arnau de Vilanova, Lleida, Spain; Hospital Lozano Blesa, Zaragoza, Spain; Astrazeneca, Macclesfield, United Kingdom
| | - I. Smith
- Royal Marsden Hospital, London, United Kingdom; Royal Bournemouth Hospital, Bournemouth, United Kingdom; Hospital Arnau de Vilanova, Lleida, Spain; Hospital Lozano Blesa, Zaragoza, Spain; Astrazeneca, Macclesfield, United Kingdom
| | - A. Skene
- Royal Marsden Hospital, London, United Kingdom; Royal Bournemouth Hospital, Bournemouth, United Kingdom; Hospital Arnau de Vilanova, Lleida, Spain; Hospital Lozano Blesa, Zaragoza, Spain; Astrazeneca, Macclesfield, United Kingdom
| | - A. Llombart
- Royal Marsden Hospital, London, United Kingdom; Royal Bournemouth Hospital, Bournemouth, United Kingdom; Hospital Arnau de Vilanova, Lleida, Spain; Hospital Lozano Blesa, Zaragoza, Spain; Astrazeneca, Macclesfield, United Kingdom
| | - J. Mayordomo
- Royal Marsden Hospital, London, United Kingdom; Royal Bournemouth Hospital, Bournemouth, United Kingdom; Hospital Arnau de Vilanova, Lleida, Spain; Hospital Lozano Blesa, Zaragoza, Spain; Astrazeneca, Macclesfield, United Kingdom
| | - S. Detre
- Royal Marsden Hospital, London, United Kingdom; Royal Bournemouth Hospital, Bournemouth, United Kingdom; Hospital Arnau de Vilanova, Lleida, Spain; Hospital Lozano Blesa, Zaragoza, Spain; Astrazeneca, Macclesfield, United Kingdom
| | - J. Salter
- Royal Marsden Hospital, London, United Kingdom; Royal Bournemouth Hospital, Bournemouth, United Kingdom; Hospital Arnau de Vilanova, Lleida, Spain; Hospital Lozano Blesa, Zaragoza, Spain; Astrazeneca, Macclesfield, United Kingdom
| | - E. Beresford
- Royal Marsden Hospital, London, United Kingdom; Royal Bournemouth Hospital, Bournemouth, United Kingdom; Hospital Arnau de Vilanova, Lleida, Spain; Hospital Lozano Blesa, Zaragoza, Spain; Astrazeneca, Macclesfield, United Kingdom
| | - P. Magill
- Royal Marsden Hospital, London, United Kingdom; Royal Bournemouth Hospital, Bournemouth, United Kingdom; Hospital Arnau de Vilanova, Lleida, Spain; Hospital Lozano Blesa, Zaragoza, Spain; Astrazeneca, Macclesfield, United Kingdom
| |
Collapse
|
28
|
Dowsett M, Houghton J, Iden C, Salter J, Farndon J, A'Hern R, Sainsbury R, Baum M. Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status. Ann Oncol 2006; 17:818-26. [PMID: 16497822 DOI: 10.1093/annonc/mdl016] [Citation(s) in RCA: 214] [Impact Index Per Article: 11.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND Most women with oestrogen receptor (ER) positive primary breast cancer receive adjuvant tamoxifen after surgery. The measurement of tumour biomarkers should allow better selection of patients for such treatment or for therapies such as aromatase inhibitors. PATIENTS AND METHODS Histopathological blocks of primary breast cancer patients who had been randomized to receive 2-years tamoxifen or no adjuvant therapy in two mature randomised clinical trials were retrieved. Immunohistochemical staining for ER, progesterone receptor (PgR), HER2 and epidermal growth factor receptor (EGFR) was undertaken. The primary endpoint was relapse free survival. RESULTS 813 patients were included in the study. Benefit from tamoxifen was seen in ER-positive patients [Relative risk (rr) 0.77, ci 0.63-0.93]. ER-negative patients also showed a strong trend to benefit from tamoxifen (rr 0.73, ci 0.52-1.02) which was largely confined to the PgR-positive group. Amongst the ER-positive group, PgR-positive and PgR-negative patients showed similar benefit (rr 0.81; ci 0.65-1.02 and 0.70; ci 0.49-0.99, respectively). Patients positive for HER2 did not benefit significantly (rr 1.14; ci 0.75-1.73) but this group was small. CONCLUSIONS Measurement of PgR status in ER-negative patients defines a group of patients that benefit from tamoxifen but would be excluded from tamoxifen therapy on the basis of ER status alone. The data are consistent with HER2 positive tumours being resistant to tamoxifen.
Collapse
Affiliation(s)
- M Dowsett
- Academic Department of Biochemistry, The Royal Marsden NHS Trust, London, UK.
| | | | | | | | | | | | | | | |
Collapse
|
29
|
Dowsett M, Johnston S, Martin LA, Salter J, Hills M, Detre S, Gutierrez MC, Mohsin SK, Shou J, Allred DC, Schiff R, Osborne CK, Smith I. Growth factor signalling and response to endocrine therapy: the Royal Marsden Experience. Endocr Relat Cancer 2005; 12 Suppl 1:S113-7. [PMID: 16113087 DOI: 10.1677/erc.1.01044] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
De novo resistance to endocrine therapy is a near-universal feature of oestrogen receptor (ER)- negative breast cancer. Although many ER-positive breast cancers also show no response to tamoxifen or aromatase inhibitors on objective clinical grounds the large majority show reduced proliferation indicating that some oestrogen dependence is present in almost all ER-positive breast cancer. In neoadjuvant studies HER2 positivity is associated with poor response rates to tamoxifen but not aromatase inhibitors, consistent with preclinical models. Acquired resistance to tamoxifen is associated with decreases in ER positivity but most recurrent lesions remain ER-positive. A small proportion of these show increased HER2 expression and in these patients increased phospho-p38 may contribute to the tamoxifen-resistant phenotype. There is an unfortunate paucity of clinical and biological data on acquired resistance to aromatase inhibitors.
Collapse
Affiliation(s)
- M Dowsett
- Academic Department of Biochemistry, Royal Marsden Hospital, London SW3 6JJ, UK.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Abstract
BACKGROUND Tegaserod, a 5-hydroxytryptamine-4 receptor agonist, enhances gastric emptying, but its effects on proximal stomach function have not been studied. AIM To study the effect of tegaserod on gastric compliance, accommodation and perception of distension in humans. METHODS Nineteen healthy volunteers (10 females; mean age, 23.9 years) were studied on three separate occasions after 7 days of treatment with placebo, tegaserod 2 mg b.d. or tegaserod 6 mg b.d. in a double-blind, randomized, three-way cross-over design. After the introduction of a barostat bag, stepwise distensions were performed to determine gastric compliance and sensitivity, and a mixed liquid meal was administered in isobaric mode to assess accommodation. RESULTS Tegaserod had no effect on the pressures or volumes inducing first perception or discomfort. Tegaserod 6 mg b.d. enhanced fasting gastric compliance compared with placebo. Pre-prandial and post-prandial intra-balloon volumes were significantly higher after 6 mg b.d. than after placebo. Both tegaserod 2 and 6 mg b.d. shortened the time to maximum post-prandial intra-balloon volume. The amplitude of meal-induced gastric relaxation (post-prandial minus pre-prandial volumes) did not differ between the treatment arms. CONCLUSION In humans, tegaserod allows for larger intra-balloon volumes both before and after a meal. These findings warrant the investigation of the therapeutic potential of tegaserod in dyspeptic patients with impaired accommodation.
Collapse
Affiliation(s)
- J Tack
- Division of Gastroenterology, UZ Gasthuisberg, Leuven, Belgium.
| | | | | | | | | | | |
Collapse
|
31
|
Assersohn L, Salter J, Powles TJ, A'hern R, Makris A, Gregory RK, Chang J, Dowsett M. Studies of the Potential Utility of Ki67 as a Predictive Molecular Marker of Clinical Response in Primary Breast Cancer. Breast Cancer Res Treat 2003; 82:113-23. [PMID: 14692655 DOI: 10.1023/b:brea.0000003968.45511.3f] [Citation(s) in RCA: 53] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
INTRODUCTION Objectives were to characterise the relationship of the proliferation marker Ki67 with response to systemic treatment in early breast cancer and to assess its clinical utility, using fine needle aspirates. MATERIALS AND METHODS Hundred and six women were treated with primary tamoxifen (n = 33), chemotherapy (n = 33) or chemotherapy and tamoxifen (n = 40). Treatment was not randomised and response was assessed clinically. Ki67 was evaluated prior to treatment and at Day 14 or 21 after commencing treatment. To assess reproducibility, Ki67 was evaluated in repeat FNAs taken from 37 untreated patients. RESULTS The percentage change in Ki67 in first 21 days was different between responders and non-responders for patients treated with tamoxifen (p = 0.007) and chemotherapy (p = 0.005) but not for chemoendocrine treatment (p = 0.062). The reproducibility study indicated that a decrease to 36% or less of the pre-treatment Ki67 value in an individual patient was required for it to be regarded as a statistically significant change. A significant decrease in Ki67 was seen in responding patients treated with chemotherapy (p = 0.026) and chemoendocrine treatment (p = 0.041). Positive and negative predictive values for response were 85 and 59% for chemotherapy patients and 88 and 54% for chemoendocrine patients, respectively. CONCLUSION Ki67 is unlikely to be useful as a predictive marker in individual patients. Further molecular markers that predict lack of response continue to be required.
Collapse
Affiliation(s)
- L Assersohn
- Breast Unit, Royal Marsden Hospital, Sutton, Surrey, UK
| | | | | | | | | | | | | | | |
Collapse
|
32
|
Archer CD, Parton M, Smith IE, Ellis PA, Salter J, Ashley S, Gui G, Sacks N, Ebbs SR, Allum W, Nasiri N, Dowsett M. Early changes in apoptosis and proliferation following primary chemotherapy for breast cancer. Br J Cancer 2003; 89:1035-41. [PMID: 12966422 PMCID: PMC2376965 DOI: 10.1038/sj.bjc.6601173] [Citation(s) in RCA: 73] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
Patients undergoing primary chemotherapy for invasive breast cancer consented to a core biopsy of the invasive breast primary pre- and 24 h postchemotherapy. The resulting tissue was analysed for apoptosis, Ki67, ER and HER-2 using immunohistochemical techniques. These data were then used to evaluate the relationship between these biological markers and response to chemotherapy and overall survival. Response rate to chemotherapy in this group was 86%, 16 patients (25%) achieved a clinical complete response and 41 (63%) a partial response. Prechemotherapy there was a significant correlation between Ki67 and apoptotic index (AI), r=0.6, (P<0.001). A significant rise in AI (P<0.001), and fall in Ki67 (P=0.002) was seen 24 h following chemotherapy. No relationship was seen between pretreatment AI and clinical response, but higher Ki67 and growth index (Ki67/AI ratio, GI) did correlate with clinical response (both r=0.31, P<0.025). No correlation was seen between the change in AI or Ki67 at 24 h and clinical response or survival. Significant changes in apoptosis and proliferation can be demonstrated 24 h following chemotherapy, but these changes do not relate to clinical response or outcome in this study. Pretreatment proliferation and GI are however predictive of response to chemotherapy in breast cancer.
Collapse
MESH Headings
- Adult
- Antineoplastic Agents/therapeutic use
- Apoptosis/drug effects
- Breast Neoplasms/drug therapy
- Breast Neoplasms/metabolism
- Breast Neoplasms/pathology
- Carcinoma, Ductal, Breast/drug therapy
- Carcinoma, Ductal, Breast/metabolism
- Carcinoma, Ductal, Breast/pathology
- Carcinoma, Lobular/drug therapy
- Carcinoma, Lobular/metabolism
- Carcinoma, Lobular/pathology
- Cell Division/drug effects
- Female
- Humans
- Immunoenzyme Techniques
- Ki-67 Antigen/metabolism
- Middle Aged
- Receptor, ErbB-2/metabolism
- Receptors, Estrogen/metabolism
- Survival Rate
- Treatment Outcome
Collapse
Affiliation(s)
- C D Archer
- Breast Unit, Royal Marsden NHS Trust, Fulham Road, London SW3 6JJ, UK.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Dowsett M, Bartlett J, Ellis IO, Salter J, Hills M, Mallon E, Watters AD, Cooke T, Paish C, Wencyk PM, Pinder SE. Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres. J Pathol 2003; 199:418-23. [PMID: 12635131 DOI: 10.1002/path.1313] [Citation(s) in RCA: 188] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Accurate diagnostic assessment of HER-2 is essential for the appropriate application of the humanized anti-HER-2 monoclonal antibody trastuzumab (Herceptin) to the treatment of patients with metastatic breast cancer. The diagnostic test needs to be applicable to archival, fixed tissue removed at excision, in many cases several years earlier. We compared the assessment of HER-2 by immunohistochemistry (IHC; HercepTest) and fluorescence in situ hybridization (FISH) in 426 breast carcinomas from patients being considered for trastuzumab therapy. The tumours were tested in three reference centres having been sent in from 37 hospitals. Only 2/270 (0.7%) IHC 0/1+ tumours were FISH positive. Six of 102 (5.9%) IHC 3+ tumours were FISH negative. Five of the six had between 1.75 and 2.0 HER-2 gene copies per chromosome 17 and the sixth had multiple copies of chromosome 17. Thirteen per cent of tumours were IHC 2+ and overall 48% of these were FISH positive but this proportion varied markedly between the centres. Sixty IHC-stained slides selected to be enriched with 2+ cases were circulated between the three laboratories and scored. There were 20 cases in which there was some discordance in scoring. Consideration of the FISH score in these cases led to concordance in the designation of positivity/negativity in 19 of these 20 cases. These data support an algorithm in which FISH testing is restricted to IHC 2+ tumours in reference centres. The results may not extrapolate to laboratories with less experience or using different methodologies.
Collapse
Affiliation(s)
- M Dowsett
- Academic Department of Biochemistry, Royal Marsden NHS Trust, London, UK.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Diamond S, Salter J, Hummel D. The role of pharmacists in anaphylaxis education. J Allergy Clin Immunol 2003. [DOI: 10.1016/s0091-6749(03)80289-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
35
|
Taylor J, Faughey-Scraggs M, Salter J, Russell J, Granger D, Homer-Vanniasinkam S. Vascular 05. Br J Surg 2002. [DOI: 10.1046/j.1365-2168.89.s.1.33_1.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
36
|
Dowsett M, Harper-Wynne C, Boeddinghaus I, Salter J, Hills M, Dixon M, Ebbs S, Gui G, Sacks N, Smith I. HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer. Cancer Res 2001; 61:8452-8. [PMID: 11731427] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/22/2023]
Abstract
In experimental models, human epidermal growth factor receptor-2 (HER-2) amplification leads to estrogen independence and tamoxifen resistance in estrogen receptor (ER)-positive human breast cancer cells. Some but not all reports suggest an association between HER-2 positivity and hormone independence in breast cancer patients. This study aimed to evaluate the antiproliferative effects of endocrine therapy in HER-2-positive/ER-positive primary human breast cancer. The effect on proliferation (Ki67) of hormone therapy was assessed at 2 weeks and/or 12 weeks in biopsies from 115 primary breast cancers with ER-positive tumors. The patients took part in one of 3 neoadjuvant trials of hormonal therapy with a SERM (tamoxifen or idoxifene) or an aromatase inhibitor (anastrozole or vorozole). HER-2 status was assessed by immunocytochemistry and fluorescence in situ hybridization (FISH). Fifteen patients were defined as HER-2 positive by both immunohistochemistry and FISH, with the remaining 100 patients HER-2 negative. Geometric mean Ki67 levels were substantially higher in HER-2-positive than HER-2-negative tumors (27.7% versus 11.5%, respectively; P = 0.003). In HER-2-negative patients, Ki67 was reduced by 62 and 71% at 2 and 12 weeks, respectively (P < 0.0001 for both), but HER-2-positive patients showed no significant fall. The proportional change in Ki67 was significantly different between HER-2-positive and -negative patients (P = 0.014 at 2 weeks; P = 0.047 at 12 weeks). Mean ER levels were lower in the HER-2-positive patients (P = 0.06) but the change in Ki67 was impeded even in those with high ER. Apoptotic index was reduced by 30% at 2 weeks in the HER-2-negative group. However, there were no statistically significant differences in apoptotic index between the groups. It is concluded that ER-positive/HER-2-positive primary breast carcinomas show an impeded antiproliferative response to endocrine therapy that nonetheless may vary between individual treatments. This together with high baseline proliferation is likely to translate to poor clinical response.
Collapse
Affiliation(s)
- M Dowsett
- Breast Unit, Royal Marsden Hospital, London, United Kingdom.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Dowsett M, Ellis I, Bartlett J, Salter J, Lowe F, Wencyk P, Pinder S, Paish C, Walters A, Cooke T. Correlation between immunohistochemical and fish analysis for HER-2 in 441 breast carcinomas from multiple hospitals. Eur J Cancer 2001. [DOI: 10.1016/s0959-8049(01)80042-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
38
|
Abstract
Dietary carbohydrates that escape digestion and absorption in the small intestine include non-digestible oligosaccharides (carbohydrates with a degree of polymerisation between three and ten), resistant starch and non-starch polysaccharides. The physiological effects of this heterogeneous mixture of substrates are partly predictable on the basis of their physicochemical properties. Monosaccharide composition and chain conformation influence the rate and extent of fermentation. Water-holding capacity affects stool weight and intestinal transit time. Viscous polysaccharides can cause delayed gastric emptying and slower transit through the small bowel, resulting in the reduced rate of nutrient absorption. Polysaccharides with large hydrophobic surface areas have potentially important roles in the binding of bile acids, carcinogens and mutagens. Ispaghula is capable of binding bile acids through a large number of weak binding sites on the polysaccharide structure, and having greatest effect on the potentially more harmful secondary bile acids deoxycholic acid and lithocholic acid.
Collapse
Affiliation(s)
- A D Blackwood
- Food Research Centre, South Bank University, 103 Borough Road, London SE1 0AA, England
| | | | | | | |
Collapse
|
39
|
Dowsett M, Dixon JM, Horgan K, Salter J, Hills M, Harvey E. Antiproliferative effects of idoxifene in a placebo-controlled trial in primary human breast cancer. Clin Cancer Res 2000; 6:2260-7. [PMID: 10873076] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/16/2023]
Abstract
Idoxifene is a novel selective estrogen receptor modulator. It has reduced agonist activity on breast and uterine cells compared with tamoxifen and antiproliferative effects in tamoxifen-resistant breast cancer cells. Previous studies have shown that a short course of treatment with other antiestrogens prior to surgery caused a significant reduction of the growth fraction when measured by immunohistological staining using the mouse monoclonal antibody Ki67. In this study, we assessed the effect of idoxifene on biological markers of cell proliferation (Ki67) and apoptosis (TdT-mediated dUTP-biotin nick end labeling), and estrogen and progesterone receptor (ER/PR) expression was also evaluated. Core-cut biopsies were obtained in 77 postmenopausal patients with primary breast cancer at diagnosis. Patients were randomized to 40 mg/day idoxifene or placebo for 14-21 days prior to obtaining a second biopsy sample at surgical resection. The percentage of Ki67-positive cells fell from a mean 19.7 +/- 2.7% (SE) to 13.4 +/- 3.4% in idoxifene-treated ER-positive tumors (n = 30; P = 0.0043), but there was no significant effect in placebo-treated ER-positive tumors (n = 27). No effect was seen on ER-negative tumors in either group. Idoxifene had no significant effect on apoptotic index but produced a statistically significant fall in idoxifene-treated ER immunohistochemical score and a small increase in PR that did not reach statistical significance (0.05 < P < 0.10). Idoxifene was well tolerated in all patients. Idoxifene has an antiproliferative effect in ER-positive but not ER-negative breast cancers, and no significant effect on apoptosis in the short-term.
Collapse
Affiliation(s)
- M Dowsett
- Department of Academic Biochemistry, Royal Marsden Hospital, London, United Kingdom.
| | | | | | | | | | | |
Collapse
|
40
|
Hahn TL, Whitfield R, Salter J, Granger DN, Unthank JL, Lalka SG. Evaluation of the role of intercellular adhesion molecule 1 in a rodent model of chronic venous hypertension. J Surg Res 2000; 88:150-4. [PMID: 10644481 DOI: 10.1006/jsre.1999.5766] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
PURPOSE To evaluate the role of intercellular adhesion molecule 1 (ICAM-1) in cutaneous leukocyte trapping in venous disease, we used our rodent model of venous hypertension (VH). MATERIALS AND METHODS VH was created in adult rats by ligation of the inferior vena cava, bilateral common iliac veins, and bilateral common femoral veins. In the Phase I experimental (exptl) group, anti-ICAM-1 monoclonal antibody (1A29) was given intravenously prior to venous ligations. Acute venous pressures were measured in the exptl and control (ctrl) (ligation only) groups. Bilateral forelimb and hindlimb skin specimens were harvested for myeloperoxidase (MPO) assay. In Phase II, VH was created in a chronic group; in a sham-operated group, ties were placed around the same vessels without ligations. Two weeks later, venous pressures were measured and radiolabeled ((125)I and (131)I) monoclonal antibody (mAb) to ICAM-1 was injected and allowed to circulate for 5 min before the level of radiolabeled antibody within forelimb and hindlimb specimens was measured. RESULTS In the acute study with 1A29, hindlimb pressures were significantly elevated in both the ctrl (n = 4) and exptl (n = 4) hindlimbs (15.4 +/- 0.239 and 13.8 +/- 1.89 mm Hg, respectively) compared with ctrl and exptl forelimbs (1.38 +/- 0.554 and 1.50 +/- 0.612 mm Hg, respectively). However, MPO activity was significantly elevated in the hindlimbs of the ctrl group compared with the hindlimbs of the exptl animals (19.8 +/- 1.54 U vs 6.71 +/- 2.46 U). In the chronic VH rats (n = 5) given radiolabeled anti-ICAM-1 mAb, the hindlimb pressures (10.1 +/- 4.52 mm Hg) were significantly elevated (P < 0.05) compared with forelimb pressures (1 +/- 0.447 mm Hg) and compared with the forelimb and hindlimb pressures in the sham-operated animals (n = 4) (1.63 +/- 0.813 and 4.25 +/- 2.13 mm Hg, respectively). However, there was not a significant difference in the quantity of ICAM-1-hindlimb versus forelimb or chronic VH versus sham. CONCLUSIONS Anti-ICAM-1 mAb decreased MPO activity in hypertensive hindlimb skin, supporting the instrumental role of ICAM-1 in cutaneous leukocyte trapping. However, the constituent endothelial ICAM-1 is not elevated by VH.
Collapse
Affiliation(s)
- T L Hahn
- Division of Vascular Surgery, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA
| | | | | | | | | | | |
Collapse
|
41
|
Gregory RK, Powles TJ, Salter J, Chang JC, Ashley S, Dowsett M. Prognostic relevance of cerbB2 expression following neoadjuvant chemotherapy in patients in a randomised trial of neoadjuvant versus adjuvant chemoendocrine therapy. Breast Cancer Res Treat 2000; 59:171-5. [PMID: 10817352 DOI: 10.1023/a:1006394317282] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
Recent advances in the detection and treatment of breast cancer have led to an intensive search for new markers of both prognosis and chemoresponsiveness. The oncogene cerbB2 has proved to be one of the most promising markers currently under study, both as a predictor of chemoresponsiveness and as a marker of poor prognosis. In addition the increasing use of neoadjuvant chemotherapy has led to the loss of standard prognostic criteria. In order to study the potential role of cerbB2 expression as an indicator of chemoendocrine resistance and poor prognosis, both before and after chemotherapy, we obtained tumour sections from 283 women enrolled onto a neoadjuvant trial. In this trial patients were randomised to receive either primary surgery followed by adjuvant chemoendocrine treatment or neoadjuvant chemoendocrine therapy followed by surgery. CerbB2 status was determined immunohistochemically on all of these patients. Thirty-eight percent of the tumours were cerbB2 positive. There was no significant difference in expression between the adjuvant (41%) and neoadjuvant arms (35%). CerbB2 positive patients were much more likely to have shown non-response to chemoendocrine therapy (p < 0.001) and had a worse DES (p < 0.05). The best prognosis was seen in cerbB2 negative patients receiving neoadjuvant chemoendocrine therapy who showed a significantly better DFS (p < 0.05), than the cerbB2 negative patients receiving adjuvant therapy.
Collapse
Affiliation(s)
- R K Gregory
- Breast Unit, Royal Marsden Hospital, Sutton, Surrey, UK
| | | | | | | | | | | |
Collapse
|
42
|
Detre S, Salter J, Barnes DM, Riddler S, Hills M, Johnston SR, Gillett C, A'Hern R, Dowsett M. Time-related effects of estrogen withdrawal on proliferation- and cell death-related events in MCF-7 xenografts. Int J Cancer 1999; 81:309-13. [PMID: 10188736 DOI: 10.1002/(sici)1097-0215(19990412)81:2<309::aid-ijc23>3.0.co;2-s] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
Endocrine treatments for human breast cancer have been based largely upon the removal of estrogenic stimuli. The regression of tumors after estrogen deprivation has generally been characterized as being due to reduced proliferation but more recently has been recognized to also involve increased apoptosis. The aim of our experiments was to define the associated changes in certain proliferation- and cell death-related biological parameters after hormone withdrawal from estrogen-dependent MCF-7 xenografts in athymic nude mice using immunohistochemical techniques. The baseline estrogen receptor (ER) level of this MCF-7 xenograft was relatively low (average H score 23) but it was strongly Bcl-2-, PgR- and pS2-positive, indicating the functional integrity of estrogen signaling. Changes in proliferation (Ki-67), apoptosis, ER, progesterone receptor (PgR), cyclin D1, p27kip1, Bcl-2 and Bax expression were assessed during the 2 weeks after estrogen deprivation. ER levels rose markedly after estrogen ablation, whereas PgR levels fell to about 10% of baseline and pS2 levels halved. The proportion of Ki-67-positive cells was unchanged after 24 hr but by day 14 had reduced by about 80%. The normal levels of cyclin D1 also reduced after estrogen withdrawal in contrast to the rapid increase in levels of cyclin-dependent kinase inhibitor p27kip1. This latter increase appeared to occur in advance of the changes in Ki-67. The proportion of apoptotic cells increased from a mean 1.5% at baseline to 2.9% after 3 days and 4.7% after 14 days. There were reductions in both Bcl-2 and Bax staining but these appeared to be greater for Bcl-2, effectively decreasing the Bcl-2/Bax ratio. Our results provide a framework for the use of these parameters as intermediate markers in comparisons of hormonal agents for human breast cancer treatment.
Collapse
Affiliation(s)
- S Detre
- Academic Department of Biochemistry, Royal Marsden Trust, London, UK
| | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Dowsett M, Archer C, Assersohn L, Gregory RK, Ellis PA, Salter J, Chang J, Mainwaring P, Boeddinghaus I, Johnston SR, Powles TJ, Smith IE. Clinical studies of apoptosis and proliferation in breast cancer. Endocr Relat Cancer 1999; 6:25-8. [PMID: 10732783 DOI: 10.1677/erc.0.0060025] [Citation(s) in RCA: 40] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
The interaction between cell death and cell proliferation determines the growth dynamics of all tissues. Studies are described here which relate the changes in proliferation and apoptosis that occur in human breast cancer during medical therapeutic manoeuvres. Xenograft studies strongly support the involvement of increased apoptosis as well as decreased proliferation after oestrogen withdrawal, and limited studies in clinical samples confirm the involvement of both processes. Cytotoxic chemotherapy induces increases in apoptosis within 24 h of starting treatment. However, after 3 months therapy the residual cell population shows apoptotic and proliferation indices much below pretreatment levels. Further molecular studies of this "dormant" population are important to characterise the mechanism of their resistance to drug therapy. The early changes in proliferation and apoptosis may provide useful intermediate response indices.
Collapse
Affiliation(s)
- M Dowsett
- Academic Department of Biochemistry, Royal Marsden Hospital, London, UK
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Harper-Wynne C, Hills M, Nasiri N, Salter J, Dowsett M. Estimation of proliferative activity in normal postmenopausal breast tissue using core biopsy. Breast 1999. [DOI: 10.1016/s0960-9776(99)90336-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
45
|
Salter J. Sympathy with the poor: theories of punishment in Hugo Grotius and Adam Smith. Hist Polit Thought 1999; 20:205-224. [PMID: 21275211] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
|
46
|
Ellis PA, Smith IE, Detre S, Burton SA, Salter J, A'Hern R, Walsh G, Johnston SR, Dowsett M. Reduced apoptosis and proliferation and increased Bcl-2 in residual breast cancer following preoperative chemotherapy. Breast Cancer Res Treat 1998; 48:107-16. [PMID: 9596482 DOI: 10.1023/a:1005933815809] [Citation(s) in RCA: 80] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Experimental laboratory data suggest that tumour growth is a balance between apoptosis and proliferation and that suppression of drug-induced apoptosis by oncogenes such as bcl-2 may be an important cause of intrinsic chemoresistance. The aims of this study were to assess the in vivo relationship of apoptosis to proliferation and Bcl-2 protein in human breast tumours both prior to chemotherapy and in the residual resistant cell population at the completion of treatment. We examined apoptotic index (AI), Ki67 and Bcl-2 protein expression in the tissue of 40 patients with operable breast cancer immediately before ECF preoperative chemotherapy, and in 20 of these patients with residual tumour, at the completion of treatment. There was a significant positive association between AI and Ki67 both before and after chemotherapy, and in their percentage change with treatment. In the residual specimens AI and Ki67 were significantly reduced compared with pre-treatment biopsies, while Bcl-2 expression showed a significant increase. No differences were seen in the pre-treatment levels of any of the variables measured between patients obtaining pathological complete response and those who did not, although numbers were small. These data suggest that apoptosis and proliferation are closely related in vivo. It is possible that the phenotype of reduced apoptosis and proliferation, and increased Bcl-2 may be associated with breast cancer cells resistant to cytotoxic chemotherapy, although this can only be proven by assessing larger numbers of patients in relation to pathological response.
Collapse
Affiliation(s)
- P A Ellis
- Academic Department of Biochemistry, The Breast Unit, Royal Marsden Hospital, London, UK
| | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Ellis PA, Saccani-Jotti G, Clarke R, Johnston SR, Anderson E, Howell A, A'Hern R, Salter J, Detre S, Nicholson R, Robertson J, Smith IE, Dowsett M. Induction of apoptosis by tamoxifen and ICI 182780 in primary breast cancer. Int J Cancer 1997; 72:608-13. [PMID: 9259399 DOI: 10.1002/(sici)1097-0215(19970807)72:4<608::aid-ijc10>3.0.co;2-7] [Citation(s) in RCA: 85] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Hormonal breast cancer therapies have traditionally been considered cytostatic, but recent pre-clinical data suggest that anti-oestrogens can induce apoptosis. The aim of this study was to assess whether tamoxifen (TAM) and ICI 182780 (ICI) could induce apoptosis in human breast cancer, and whether this was related to oestrogen receptor status. We measured apoptosis in primary breast cancer patients before and after pre-surgical treatment with 20 mg/day TAM (study 1) or 6 or 18 mg/day ICI (study 2). In each study there was a randomised non-treatment (NT) control group. TAM significantly increased apoptotic index (AI) in ER+ but not in ER- tumours. There was a significant increase in AI following treatment with ICI. Insufficient pairs of samples were available to determine whether this change was confined to ER+ tumours, but in a cross-sectional analysis AI was significantly higher in excision biopsies for ICI-treated than NT patients for ER+ but not ER- tumours. Our results provide clinical evidence that apoptosis may be induced in ER+ primary breast cancer by both non-steroidal and steroidal anti-oestrogens.
Collapse
Affiliation(s)
- P A Ellis
- Department of Biochemical Endocrinology, Royal Marsden NHS Trust, London, UK
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Turkoski B, Pierce LL, Schreck S, Salter J, Radziewicz R, Guhde J, Brady R. Clinical nursing judgment related to reducing the incidence of falls by elderly patients. Rehabil Nurs 1997; 22:124-30. [PMID: 9171720 DOI: 10.1002/j.2048-7940.1997.tb02081.x] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
The incidence of falls among elderly patients has been and continues to be a major challenge for nurses. Falls add physical injury and mental stress to patients' existing health problems, are a deterrent to rehabilitation, and increase healthcare costs. This study describes the variables that nurses identify as influencing their clinical decision making and the nursing behaviors associated with preventing patient falls. The study was grounded in the theory that discretionary nursing behaviors are related to nursing expertise, and the study was guided by the assumption that such behaviors are proactive and anticipatory. An analysis of interviews of registered nurses (n = 14) working on a geriatric rehabilitation unit in a medical center in Ohio focused on the zones of association and the contextual meanings of language used by the nurses when discussing patient falls. Four themes emerged: the reasons for patient falls, identifying patients who are likely to fall, preventing falls, and nurses' feelings when patients fall.
Collapse
Affiliation(s)
- B Turkoski
- Kent State University School of Nursing, OH 44240, USA
| | | | | | | | | | | | | |
Collapse
|
49
|
|
50
|
Dowsett M, Makris A, Ellis P, Johnston SR, Salter J, Detre S, Humphries S, Saccani-Jotti G, Powles TJ, Smith IE. Oncogene products and other diagnostic markers in human breast cancer patients. Treatment effects and their significance. Ann N Y Acad Sci 1996; 784:403-11. [PMID: 8651589 DOI: 10.1111/j.1749-6632.1996.tb16254.x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Affiliation(s)
- M Dowsett
- Academic Department of Biochemistry, Royal Marsden Hospital, London, England
| | | | | | | | | | | | | | | | | | | |
Collapse
|